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1. Introduction 
Human immunodeficiency virus (HIV) is the cause of acquired immunodeficiency syndrome 
(AIDS).  Blood monocytes and resident macrophages are important in vivo cell targets for HIV 
infection and their role in AIDS pathogenesis are well documented. These cells of innate 
immune defenses usually survive HIV infection, serve as a major virus reservoir, and function 
as immunoregulatory cells through secretion of several pro-inflammatory cytokines and 
chemokines in response to HIV infection, thereby recruiting and activating new target cells for 
the virus, including CD4+ T cells. This review describes the alterations in the synthesis of host 
cytokines and chemokines following HIV infection thereby favoring successful survival of the 
virus inside the host and enhancing the susceptibility of the host to opportunistic infections.  
2. HIV and chemokine receptors 
HIV infects immune cells of the macrophage and T-cell lineage. Entry into these cells 
requires CD4 as a receptor in addition to a co-receptor which most frequently is either 
chemokine receptor CCR5 or CXCR4 (Gorry & Ancuta, 2011).   Binding and entry into 
human cells requires the two HIV envelope glycoproteins gp120 and gp41. Gp41 possesses a 
transmembrane domain and is associated with the viral envelope while Gp120 is present in 
association with Gp41 but does not insert into or contact the viral membrane (Tagliamonte et 
al; 2010).  These two viral glycoproteins are present in HIV as tetramers. Therefore, three 
Gp41 molecules associate within the viral membrane, while three molecules of Gp120 
associate with Gp41 (Tagliamonte et al; 2010).  To facilitate HIV-1 entry into human cells, 
Gp120 binds to human cellular CD4 with high affinity. Binding causes a conformational 
change in Gp120 that reveals a co-receptor binding site. Binding to one of the chemokine 
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receptors is then facilitated which in turn induces a conformational change in the 
glycoprotein gp41 N-terminus (Tagliamonte et al; 2010).  A fusion peptide portion of gp41 
inserts into the host cell membrane and lowers energy that is required for fusion of the host 
and viral membranes (Tagliamonte et al; 2010).  The viral core is then translocated into the 
cytoplasm of the host cell.   
HIV-1 viral variants can in general use either the CCR5 or CXCR4 co-receptor for entry into 
human cells (Gorry & Ancuta, 2011).  They may also at times use a variety of other chemokine 
receptors for entry (Gorry et al; 2007). The normal function of chemokine receptors is to bind 
chemokines that target immune cells to areas of inflammation within the human body.  
Certain HIV-1 viruses may have an increased ability to either bind the CCR5 receptor and are 
known as R5 viruses, bind to CXCR4 and are known as X4 viruses, or bind with mixed affinity 
to either receptor.  This differential affinity lies within the specific alterations in amino acid 
sequence of the gp120 glycoprotein (Gorry & Ancuta, 2011). Although not correlating 
completely, macrophage tropic HIV-1 viruses generally are R5 and T-cell tropic viruses are X4 
viruses (Gorry & Ancuta, 2011).  Early during infection R5 viruses predominate, and it appears 
that there is some mechanism which selects these viruses during the transmission process 
(Grivel et al; 2010). For example, an HIV-1 naive individual may be exposed to both R5 and X4 
virus particles from an infected individual, but only become infected with the R5 viral 
particles.  There may be multiple factors which affect this process, including co-receptor 
availability and pH at the sites of infection. Acidic pH may act to disrupt the cationic charge 
present in gp120 proteins which bind to CXCR4 preferentially (Kwong et al; 2010, Edo-Matas et 
al; 2010). R5 viruses are also prominent during chronic infection.  X4 viruses or R5X4 viruses 
which have mixed affinity can arise later during infection and often their presence precedes 
disease progression and immune cell depletion (Mariani, 2010).   
Deletion of the CCR5 receptor can in many cases abrogate infection with HIV-1 completely.  
It has previously been identified that individuals homozygous for a 32 base pair deletion 
within the CCR5 gene resulting in a nonfunctional CCR5 molecule are resistant to infection 
with the HIV-1 virus, though there have been some instances where homozygous CCR532 
individuals were infected with X4 HIV-1 (Samson, 1996).  Additionally, people who carry 
one allele of CCR532 have a slower progression of the disease.  This knowledge has led to 
the development of treatments for HIV-1 infection.  Transplantation of stem cells from 
individuals homozygous for CCR532 into CCR5 HIV-1 positive individuals resulted in 
clearing of the virus from the infected patients (Hutter, 2009).  Monoclonal antibodies 
against CCR5 to inhibit binding of HIV-1 to this co-receptor are a potential therapeutic to 
prevent viral entry and replication (Tenorio, 2011, Suleiman, 2010).  In addition there are 
plans to use an individual’s native stem cells as a target to disrupt the CCR5 receptor gene 
which can then be transplanted back into the HIV infected patient to effect elimination of the 
HIV-1 virus from the body (Cannon and June, 2011).  Pitfalls of these therapies include the 
problem that the CCR5 chemokine receptor has a native function within the body, and that 
disrupting this receptor may cause unforeseen deficits in the immune system.  In fact, lack 
of the CCR5 receptor gene has been associated with increased risk of severe infection with 
other viruses such as the West Nile Virus, and certain flaviviruses (Lin et al; 2008, Kindberg 
et al; 2008).  Notwithstanding the previously mentioned caveat, interference with the CCR5 
receptor may indeed be a promising target to treat those infected with HIV-1 as well as 
prevent infection for those exposed to the virus via sexual activity, needle sharing, or 
accidental hospital transmission.  
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3. Chemokine ligand-2 (CCL2) 
CCL2 or monocyte chemotactic protein-1 (MCP-1), of the C-C chemokine family, is a 
cytokine with the ability to influence both innate and adaptive immune responses (Daly et 
al; 2003). This chemokine is produced by a variety of different cell types including 
endothelial cells, fibroblasts, epithelial cells, smooth muscle cells, mesangial cells, astrocytic 
cells, and microglial cells. However, despite the wide range of cell types that have the ability 
to manufacture CCL2, the majority of CCL2 is produced by macrophages and monocytes 
(Deshmane et al; 2009). 
Although technically a chemokine, CCL2 is often classified as an inflammatory cytokine due 
to its ability to attract various leukocytes (monocytes, memory T cells, basophils, natural 
killer (NK) cells etc.) to sites of trauma, bacterial and mycobacterial infection, toxin 
exposure, and ischemia (Daly et al; 2003, Deshmane et al; 2009, Mahad et al; 2003,, Charo et al; 
2006). Besides attracting various leukocytes, CCL2 also specifically regulates the infiltration 
of monocytes, memory T lymphocytes, and NK cells (Deshmane et al; 2009). In addition, 
CCL2 has been found to have a profound effect on the differentiation of naïve helper T cells 
(Daly et al; 2003). Interestingly, studies have found that CCL2 expression tends to lead to the 
development of a Th2 immune response. Taking this tendency into account, it seems likely 
that CCL2 concentrations in HIV patients, which Weiss et al. (Weiss et al; 1997) found were 
correlated with viral load, can be linked to the Th1 to Th2 cytokine response switch often 
observed in HIV-1-infected patients (Deshmane et al; 2009).  
CCL2 has also been found to play other roles in HIV pathogenesis. Eugenin et al. (Eugenin et 
al; 2006) noted that CCL2 in the central nervous system (CNS) attracts HIV-infected 
leukocytes into the brain thereby increasing the rate of HIV-1-infected cell-dispersal and 
causing the eventual impairment of the blood-brain-barrier. In fact, multiple studies indicate 
that CCL2 is largely responsible for the development of HIV encephalitis (HIVE), HIV-1-
associated dementia (HAD), and NeuroAIDS (Deshmane et al; 2009, Eugenin et al; 2006).  
4. HIV and the Th1 to Th2 Cytokine shift 
Under normal conditions, the immune system utilizes a Th1 subset response to viral 
infections.  Activated antigen presenting cells (APC) secrete interleukin-12 (IL-12) which 
causes Th cell differentiation into the Th1 subset of cells (Clerci et al; 1993).  These Th1 cells 
then secrete a characteristic Th1 profile of cytokines consisting of interleukin-2 (IL-2), 
interferon-gamma (IFN-), and tumor necrosis factor-beta (TNF-ǃ).  IL-2 induces 
proliferation of naïve Th cells (T0), amplifying the Th response.  IFN- induces further IL-12 
production in activated APCs, amplifying the Th1 response, and suppressing any Th2 
response. IFN- also plays an important role in the activation of cytotoxic TC cells which 
destroy virally infected cells.   
In individuals infected with HIV, the normal Th1 response to viral infection is shifted to a 
Th2 response (Klein et al; 1997, Osakwe et al; 2010).  Measurement of the serum cytokine 
levels of HIV infected patients has revealed an increase in Th2 cytokines as well as a 
decrease in Th1 cytokines (Klein et al; 1997, Osakwe et al; 2010).  Assays have shown 
elevated serum IL-4 levels in HIV seropositive individuals (Clerci et al; 1993).  IL-4 in the 
presence of proliferating T0 cells leads to their differentiation into the Th2 subset.  Th2 cells 
promote B-cell proliferation, class switching, and eosinophil activation (Clerci et al; 1993).  
This Th2 response is not appropriate for control of intracellular pathogens such as HIV, and 
so allows it to persist and spread in CD4+ T-cells. 
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5. TNF- and HIV infection 
It has also been shown that HIV infection induces increased production of TNF- by 
macrophages. TNF- stimulates the production of free radicals. Moreover, enhanced levels 
of free radicals are likely to increase TNF- in various cells. TNF- consists of 233 amino 
acids and is expressed on all somatic cells, particularly on the cell membrane where it 
becomes hydrolyzed to its soluble form. TNF- is considered as one of the most highly 
studied pro-inflammatory cytokines because it plays a critical role in the origin and 
progression of diseases such as HIV-1 (Bahia and Silakari, 2010). The immuno-regulatory 
response of the host influences the pathogenesis of HIV-1 infection, triggering monocytes, 
macrophages, and natural killer cells to produce TNF- (Alfano and Poli, 2005).  As a result, 
there is a positive correlation between HIV-1 viremia and TNF- levels in serum of HIV-1 
infected patients. This relationship suggests that reducing TNF- levels may also reduce 
occurrence of HIV-1 viremia. In excess, TNF- may cause severe inflammatory damage and 
toxicity, making control of its production and secretion highly important. Regulating its 
release serves as a potential means of therapy for HIV-1 and other diseases. TNF- can also 
induce other pro-inflammatory cytokines such as IL-6 and IL-8, which aid in the 
upregulation of viral replication (Fernandez-Ortega et al; 2004).  Studies have also shown 
the ability of TNF- to stimulate production of anti-inflammatory cytokine IL-10, preventing 
further inflammation by causing TNF- inhibition (Leghmari et al; 2008). TNF- is secreted 
during the early phase of acute inflammatory diseases. Its pathogenic role in HIV-1 infection 
involves activation of nuclear factor kB (NF-B), stimulating apoptosis of T lymphocytes. 
Tissue and plasma samples of hosts express high levels of TNF-, contributing to fever, 
anorexia, and other symptoms of HIV/AIDS. TNF- must be targeted at an appropriate 
time during production to prevent progression to the chronic stage. Local effect of the 
cytokine may be beneficial to the host, so monitoring its development is critical. Highly 
active antiretroviral therapy helps to reduce mortality rates, and development of potent 
antiretroviral drugs blocking HIV transcription continues to be successful. However, drug 
resistance and toxicity remains a challenge in this field of medicine (Fernandez-Ortega et al; 
2004). 
6. Interleukin 1 (IL-1) and HIV infection 
HIV infection and its viral proteins can disturb the production of cytokines and disrupt their 
usual interactions resulting in disruption of the normal immune function. IL-1 and TNF-ǂ 
are produced by activation of mononuclear phagocytes as well as microglia in the brain in 
response to normal immune stimuli such as immune complexes, lipopolysaccharides and 
phorbol esters (Burchett et al; 1998).  It has been reported that IL-1 and TNF-ǂ will be 
produced by either the binding of gp120 to the CD4 molecules on mononuclear phagocytes 
or infection with HIV (Merrill et al; 1989, Cheung et al; 2008). 
IL-1 is the first discovered and most studied member of the cytokine family (Fantuzzi, 2003). 
IL-1 is a pro-inflammatory cytokine that plays a fundamental role in host defense by 
inducing acute and chronic inflammation through activation of the innate and acquired 
immune systems (Nambu and Nakae, 2010). IL-1 has been described as the prototypic pro-
inflammatory cytokine as it was originally described as the first “endogenous” pyrogen due 
to its fever-inducing properties in both rabbits and humans (Dinarello, 1999). However, in 
spite of much research in the area of fever induction, the role of IL-1 in this area is still 
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undefined (Fantuzzi, 2003). IL-1 consists of two distinct ligands (IL-1ǂ and IL-1ǃ) with two 
indistinguishable biological activities that signal through the IL-1 receptor (IL-1R1) ( Bujak 
and Frangogiannis, 2009). Both IL-1ǂ and IL-1ǃ can also bind the IL-1 receptor accessory 
protein (IL-1RAcP). Once bound to the receptor, the complex transduces a signal that 
initiates a wide variety of inflammatory genes by activating the NF-κB system. The NF-κB 
transcribed genes can produce a variety of inflammatory products including chemokines, 
pro-inflammatory cytokines, such as TNF-, IL-6 or IL-8 (Nambu and Nakae, 2010), 
adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) (Marui et al; 1993), 
colony-stimulating factors, and mesenchymal growth factor genes (Bujak and 
Frangogiannis, 2009). In addition, expression of inducible nitric oxide synthase, type 2 
cyclooxygenase (COX)-2, and type 2 phospholipase A2 is exquisitely sensitive to IL-1 (Bujak 
and Frangogiannis, 2009). IL-1 has also been associated with augmentation of the mast cell 
activation and Th2 cytokine secretion, suggesting involvement of IL-1 in allergic diseases 
such as allergic asthma (Dinarello, 1999). 
Knockouts of IL-1 have been used to study acute and chronic neurodegenerative conditions, 
in which a role for IL-1 has been well established (Fantuzzi, 2003). For example, in rodent 
studies the presence of IL-1 after occlusion of the middle cerebral artery will increase the 
ischemic damage area. It has been shown that caspase-1 cleaves the inactive pre-form to the 
active mature form of IL-1ǃ, which contributes to the damage from ischemia (Bujak and 
Frangogiannis, 2009). In resting cells, procaspase-1 is bound to an inhibitory molecule that 
prevents its activation. After damage to cells, conversion of procaspase-1 to caspase-1 is 
triggered by a molecular complex termed the “IL-1ǃ inflammasome” (Martinon, 2002). 
Macrophages and dendritic cells produce IL-1, IL-12 and other cytokines that permit CD4 
cells to reach the level of maturation needed to produce IL-2, which is needed for self-
replication of the CD4 cells and for the growth and function of CD8 cells (Levy, 2007). Thus 
IL-1 plays a role in maintaining normal immune function. 
Elevation of  IL-1 and TNF-ǂ has been demonstrated in the serum of some patients with 
HIV-1 (Lepe-Zuniga et al; 1987). High levels of IL-1 (Lepe-Zuniga et al; 1987, Weiss et al; 
1989, Molina et al; 1989, Roux-Lombard et al; 1989, Emilie et al; 1990) and TNF-ǂ ( Roux-
Lombard et al; 1989) are produced in the supernatant of cultured peripheral blood monocyte 
early in the onset of HIV disease. The levels of TNF-ǂ and IL-1 in the serum were positively 
correlated in symptomatic versus asymptomatic individuals ( Lepe-Zuniga et al; 1987). HIV 
virus is present in mononuclear phagocytes and in the blood and brain of AIDS patients. 
Production of IL-1 and TNF-ǂ from mononuclear phagocytes after stimulation with HIV-1 
may contribute to some of the symptoms of AIDS such as fever, cachexia and aseptic 
meningitis (Merrill et al; 1989).  
Chronic infection and viral latency are typical of HIV-1 infection. Stimulation with IL-1ǃ as 
well as TNF-ǂ can stimulate viral replication in chronically infected cells (Devadas et al; 
2004). Monocytes are also major reservoirs for HIV-1 in infected tissue and vectors for virus 
transmission to target cells, as well as sources of potent cytokines that can affect cell function 
and virus replication (Devadas et al; 2004). It is thought that stimulation of viral replication 
in chronically infected cells is due to activation of NF-B. In addition to IL-1 and TNF-ǂ, 
contact with macrophages as well as a number of stressors can stimulate NF-B, including 
phorbol esters, radical oxygen intermediates, and UV irradiation (Devadas et al; 2004). 
Clinical manifestations of AIDS include both immunologic and neurologic disorders. In the 
brain it has been shown that IL-1 induces activation and proliferation of astrocytes, while 
TNF-ǂ contributes to necrosis of cerebral blood vessels and possibly to demyelination 
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(Merrill et al; 1989). A feedback process has been described in which HIV-1 and TNF-ǂ can 
each induce expression of the other. It has been proposed that IL-1 will participate in this 
feedback loop by inducing TNF-ǂ or by direct T-cell activation, which is needed for HIV-1 
replication (Merrill et al; 1989). 
IL-1 has been implicated in the pathogenesis of HIV associated dementia (HAD) (Kaul et al; 
2001). Both IL-1ǃ and TNF-ǂ are highly expressed in the central nervous system (CNS) of 
individuals with HAD, correlate with neuronal injury and are implicated in the 
pathogenesis of HAD (Epstein and Gendelman, 1993,, Brabers and Nottet, 2006). HIV-1, 
recombinant gp120, and viral transactivator Tat can activate astrocytes to secrete pro-
inflammatory cytokines TNF-ǂ, IL-6, and IL-1ǃ (Corasaniti et al; 2001), which may 
contribute to the inflammatory environment in the brain (Herbein and Varin, 2010). 
Microglia and macrophages in the brain can release IL-1ǃ after stimulation with HIV-1 
envelope protein gp120 (Merrill et al; 1992, Wahl et al; 1989), which is elevated in brain 
during HIV (Tyor et al; 1992)  and has been shown to be elevated in the cerebral spinal fluid 
during HIV infection (Gallo et al; 1989).  
About 25% of subjects with HIV will develop dementia, particularly HIV encephalitis 
(HIVE), which can occur in spite of the use of HAART (Levy, 2007). Macrophage 
inflammatory products including IL-1ǃ have been demonstrated in HIV related encephalitis 
in mouse and human brain tissue (Persidsky et al; 1997). It has been suggested that the 
release of neurotoxins, including L-cysteine, from macrophages in the brain is mediated by 
IL-1 following stimulation of the macrophages by the HIV membrane protein gp120. 
L-Cysteine can be  released from  human monocyte derived macrophages stimulated by 
either gp120 (Lipton, 1998), or by IL-1 (Yeh et al; 2000). It has been suggested that cytokines 
including IL-1 may mediate the neurotoxic actions of gp120 (Yeh et al; 2000). Cysteine can 
act as an endogenous neurotoxin (Olney et al; 1990), which under both physiologic and 
pathophysiologic conditions stimulates N-methyl-D-aspartate subtype of glutamate receptor 
(NMDARs) and leads to neuronal apoptosis (Yeh et al; 2000). Thus, immune activation of 
macrophages in the brain without direct HIV infection may lead to neural damage (Yeh et 
al; 2000).    
Autopsy evaluation of brain tissue from HIVE cases shows increased IL-1ǃ in the frontal 
white matter of all 11 of the brains evaluated (67). Additionally, IL-1ǃ, but not TNF- 
expression was detected in HIVp24-positive cells in the HIVE patients, which indicates that 
IL-1ǃ is induced by HIV-1 infection. The authors concluded that a macrophage/microglia 
lineage is the main cell type to release cytokines in HIVE, and IL-1ǃ expression by HIV-1-
infected cells may be one of the important factors for induction of HIVE (67).  
7. Interleukin-6 (IL-6) 
The family of IL-6-type cytokines comprises IL-6, IL-11, LIF (leukaemia inhibitory factor), 
OSM (oncostatin M), CNTF (ciliary neurotrophic factor), CT-1 (cardiotrophin-1) and CLC 
(cardiotrophin-like cytokine) (Heinrich et al; 2003). IL-6 is a pleiotropic cytokine that is 
commonly produced at local tissue sites and released into circulation in almost all situations 
of homeostatic perturbation typically including endotoxemia, endotoxic lung, trauma, and 
acute infections. In addition to its critical participation in the generation of immunity against 
chronic intracellular infections, circulating IL-6, together with other alarm cytokines TNF- 
and IL-1, is known to be required for the induction of acute phase reactions composed of 
fever, corticosterone release, and hepatic production of acute phase proteins many of which 
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are protease inhibitors (Xing et al; 1998). They activate target genes involved in 
differentiation, survival, apoptosis and proliferation. The members of this cytokine family 
have pro- as well as anti-inflammatory properties and are major players in haematopoiesis, 
as well as in acute-phase and immune responses of the organism. IL-6-type cytokines bind 
to plasma membrane receptor complexes containing the common signal transducing 
receptor chain gp 130 (glycoprotein 130). Signal transduction involves the activation of JAK 
(Janus kinase) tyrosine kinase family members, leading to the activation of transcription 
factors of the STAT (signal transducers and activators of transcription) family. Another 
major signaling pathway for IL-6-type cytokines is the MAPK (mitogen-activated protein 
kinase) cascade (Heinrich et al; 2003). IL-6 was originally identified as ǃ2 (IFN-ǃ2), IL-1-
inducible 26kD protein and as a factor that induces the differentiation of B cells to antibody 
producing plasma cells (Hibi et al; 1996).  
The induction of IL-6 by live HIV preparations occurred in the absence of T cells and could 
be neutralized by human anti-HIV serum indicating that HIV was responsible for this IL-6 
inducing activity. It has been demonstrated that IL-6 can be produced by a variety of cells 
upon various kinds of stimulation: T cells infected with HTLV-1, fibroblasts stimulated with 
polyI:C, IL-1, platelet-derived growth factor, TNF-, FCS, or LPS, and 
monocyte/macrophages stimulated with LPS. Monocyte/ macrophages, one of the target 
cells of HIV, produced IL-6 upon stimulation with both live and inactivated HIV (Nakajima 
et al; 1989). A study of women treated for cervical intraepithelial lesions showed that after 
treatment, there were increased levels of genital HIV, TNF-ǂ, IL-6, and other activation 
markers in cervicovaginal lavage (Spear et al; 2008). In univariate analysis, genital tract HIV 
RNA was significantly associated with plasma HIV RNA and several of the cytokines, while 
in multivariate analysis, genital tract HIV RNA was significantly associated only with 
plasma HIV RNA and IL-6 (Spear et al; 2008). Another study was done to determine the 
effect of HIV on thymic stromal cells and the production of cytokines important in 
thymocyte development, three types of adherent thymic cultures were established and 
studied: thymic epithelial cells (TECs), macrophage-enriched, and mixed cultures of 
macrophages and TECs (M phi/TEC).  M phi/TEC and macrophage-enriched cultures were 
infected by both HIV strains without cytopathic changes. The TECs grew well in culture 
exposed to HIV-1 strains HIV-1IIIB and HIV-1Ba-L for at least 6 weeks and showed no 
evidence of infection, cytopathology, or changes in cytokine production with HIV. Only 
cultures containing macrophages (M phi/TEC or macrophage enriched) showed changes in 
cytokine (IL-1 alpha, IL-1 beta, and IL-6) production with HIV. Unstimulated macrophage-
enriched cultures produced small amounts of IL-6 that were increased by HIV 20-fold 
(Sandborg et al; 1994).  
There are many studies showing the increase of IL-6 expression within HIV infected cells 
but not many studies suggesting what IL-6 does to HIV. In a study done by Miles in 1990, it 
was found that IL-6 might actually be a growth factor for the HIV virus (Miles et al; 1990). 
There was a proliferative response of the AIDS-Kaposi sarcoma (AIDS-KS) cells to high 
concentrations of hrIL-6 and the detection of IL-6-rRNA in the areas of the skin involved 
with Kaposi sarcoma. AIDS-KS cells synthesized, released, and responded to biologically 
active IL-6. AIDS-KS cells, in which IL-6 protein translation arrest was induced by an IL-6 
anti sense oligodeoxynucleotide, did not proliferate optimally unless exogenous hrIL-6 was 
added (Miles et al; 1990). 
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8. Interleukin-17 (IL-17) 
IL-17 is an inflammatory cytokine that is exclusively produced by a recently discovered 
subset of CD4+ T helper (Th) cells, referred to as Th17 cells (Crome et al; 2009). This 
cytokine has been found to help regulate the inflammatory response by activating 
fibroblasts, recruiting neutrophils, and acting on macrophages to promote both their 
recruitment and survival (Crome et al; 2009, Chang et al; 2007). In addition, IL-17 is thought 
to play a significant role in activating and inducing anti-microbial peptides and pro-
inflammatory cytokines like IL-6, CCL2, and TNF- (Crome et al; 2009, Chang et al; 2007). 
Furthermore, high levels of this cytokine have been linked to a number of inflammatory 
diseases including rheumatoid arthritis, multiple sclerosis (MS), and asthma. Low levels, on 
the other hand, are thought to cause both impaired host defense against mycobacterial 
infection and decreased antibacterial immunity (Crome et al; 2009, Brenchley et al; 2008).  
Studies of the effects of HIV on IL-17 concentrations using flow cytometry have found that 
HIV-infected patients have significantly increased levels of IL-17 (Giorgio, 2003). 
Venketaraman et al. (unpublished data) was also able to show increased levels of IL-17 in 
HIV-infected blood plasma using ELISA assays. However, Brenchley et al.; 2008 noted that 
there were significantly fewer IL-17 producing Th17 cells in the gastrointestinal tract of HIV-
infected patients. In fact, the study indicated that Th17 cells were preferentially targeted 
during HIV infection.  
The decrease of IL-17 concentrations at the mucosal wall of the gastrointestinal tract could 
greatly increase the probability of bacterial infections, which could in turn have significant 
implications for the speed of HIV pathogenesis (Brenchley et al; 2008). As Levy et al; 2009 
noted, chronic immune activation increases the production of pro-inflammatory cytokines 
(IL-6, IL-17, TNF-, etc.). This up-regulation of pro-inflammatory cytokines often leads to 
the rapid loss of CD4+ T cells via apoptosis. Decreased IL-17 concentrations due to HIV 
infection can therefore ultimately lead to the general advancement of HIV by creating an 
environment favorable to opportunistic infection and chronic immune activation (Maek-A-
Nantawat et al; 2007). 
9. Interleukin-12 (IL-12) 
IL-12 is a heterodimeric pro-inflammatory cytokine that is produced by dendritic cells and 
phagocytes during an infection (Giorgio, 2003).  It is a cytokine identified as a master switch 
for leading the naïve CD4+ T cells towards the Th1 pathway and also activating NK cells 
(Villinger and Ansari, 2010).  Not only does it directly induce T, NK, and NKT cell 
cytotoxicity, IL-12 also promotes macrophage activity via T- and NK-cell-produced IFN-Ǆ 
(Giorgio, 2003, Egilmez et al; 2011).  The pathway is antagonized in the presence of IL-10 
(Villinger and Ansari, 2010).  
IL-12 plays important roles in protecting the body from various microbial infections such as 
parasites, bacteria, and viruses (Yang et al; 2010).  With mutations in genes of the IL-12, the 
cells are susceptible to intracellular pathogens such as tuberculosis, leprosy, HIV-1, hepatitis 
and malaria (Vannberg et al; 2011).  One of the characteristics of HIV infection is the gradual 
deterioration of cellular effector responses.  Studies has concluded that CD4+ and CD8+ T 
cell responses were enhanced ex vivo by the addition of IL-12, but that capacity to respond is 
decreased in patients with marked CD4 loss (Villinger and Ansari, 2010).  Louis et al;. 2010, 
also added that IL-12 production required the presence of IFN-Ǆ.  Therefore, as HIV 
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progresses, decreased IFN-Ǆ leads to decrease in IL-12 which leads to decreased CD4+ and 
CD8+ T cell response. 
A decrease of IL-12 concentration increases the probability for opportunistic infections.  
Taoufik et al; 1997 and Mirani et al; 2002, showed IL-12 mRNA was diminished while IL-10 
production was up-regulated in the presence of Staphylococcus aureus and HIV gp120, 
further inhibiting IL-12 cytokine production.  Even though IL-12 is potent, Villinger and 
Ansari 2010,  noted that when IL-12 therapy was administered in the late stages of HIV, it 
failed to restore normal levels of CD4 T cells and IFN-.   
10. Additional effects of HIV on IFN- signaling 
In addition to the Th1 subset response mediation mentioned earlier, IFN-  normally acts on 
APCs to enhance their expression of major histocompatibility complex II (MHC-II), thereby 
enhancing their antigen presentation ability (Li et al; 2011).   HIV transactivator protein 
(TAT) interferes with the intracellular signaling normally performed by the IFN- bound 
IFN- receptor (Cheng et al; 2009).  In so doing, the TAT protein lowers the antigen 
presentation capacity of dendritic cells and macrophages, further limiting the immune 
response to the invading virus (Salgame et al; 2009). 
11. The transforming growth factor β (TGF-β) 
TGF-ǃ cytokine family are closely related polypeptides which include tissue growth factors 
that have a diverse range of proteins that regulate many physiological processes including 
embryonic development, homeostasis, wound healing, chemotaxis, cell cycle control, cell 
proliferation, differentiation, apoptosis, adhesion, and migration (Leask and Abraham, 
2004). TGF-ǃ  is one of the most immunosuppressive substances produced in the body and 
yet may inhibit or stimulate cell growth, depending on the cell type and culture conditions 
(Liu and Gaston Pravia, 2010). TGF-ǃ  is produced in many immune cells including 
lymphocytes, macrophages and dendritic cells (Liu and Gaston Pravia, 2010). Receptors for 
TGF-ǃ  have been found on all cell lines tested, allowing this cytokine to have effects on 
almost any tissue in the body (Leask and Abraham, 2004). It has also been shown to play a 
central role in tissue fibrosis (Leask and Abraham, 2004).   Because of the multifunctional 
role played by TGF-ǃ, it plays a central role in the pathogenesis of many diseases.(Leask and 
Abraham, 2004).  
There are three forms of TGF-ǃ (TGF-ǃ1, TGF-ǃ2, and TGF-ǃ3) in mammalian cells. TGF-ǃs 
are synthesized using inactive precursors and cannot bind receptors until they are activated. 
After release of TGF-ǃ from cells they associate with latency-associated protein and form a 
small inactive complex. In the extracellular matrix, this complex is bound by latent TGF-ǃ-
binding protein (LTBP), a component of the extracellular matrix that is necessary for the 
secretion and storage of TGF-ǃ (Letterio and Roberts, 1998). Intracellular activity of TGF-ǃ  
is mediated by the actions of Smad transcription factors as well as independent factors ( 
Letterio and Roberts, 1998). Active Smad complexes bind to DNA weakly and high affinity 
binding is achieved by the association of Smad proteins with a large number of transcription 
factor partners (Massague, 1992). The variations of Smad proteins in transcriptional 
regulations and the diversity of Smad-independent pathways allow the pleiotropic actions 
of TGF-ǃ  ( Letterio and Roberts, 1998). 
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HIV infection leads to a variety of disturbances in cytokine expression that can lead to a 
state of chronic activation of B cells and release of cytokines that may actually play an 
important role in the pathogenesis of HIV infection (Li and Flavell, 2008). Early HIV-1 
infection is associated with a massive oligoclonal expansion of CD8 T cells (Massague and 
Gomis, 2006), however despite the high number of circulating CD8+ T cells the cytotoxic T 
lymphocyte (CTL) response is highly variable among HIV-1 infected individuals (Poli and 
Fauci, 1993). It has also been shown that the immune dysfunction in the initial phase of HIV 
infection exceeds CD4+ T cell infection and loss (Pantaleo et al; 1994 ). It appears that the 
immunosuppression effect occurs almost immediately upon infection (Garba et al; 2002). 
The result is diminished T cell response to antigen stimulation and persistence of HIV 
replication (Pantaleo and Fauci, 1995). 
HIV-1 products such as TAT, induce the transcription of cytokines with immunosuppressive 
effects, including TGF-ǃ (Cohen et al; 1999). It has been reported that extracellular TAT can 
be taken up by bystander cells and that it is possible that exogenous TAT, not associated 
with direct infection of a cell, can induce TGF-ǃ transcription in immune competent cells 
(Pantaleo et al; 1993). Macrophages appear to be very sensitive to TAT and are affected by 
TAT concentrations 1,000-fold lower (500 pM) than those that affect T cells (Cohen et al; 
1999). Macrophages stimulated by TAT either by infection or by the uptake of soluble TAT 
(sTat) induce Fas ligand (FasL), which in turn can trigger the apoptosis of antigen-reacting, 
Fas-expressing helper T cells. This mechanism would suppress T-cell dependent cellular and 
humoral immune responses to both HIV and other antigens (Cohen et al; 1999). 
The transactivating effect of HIV-1 TAT is mediated by activator protein-1, which is the 
same multimolecular complex that is activated by TGF-ǃ (Cohen et al; 1999). HIV-1 can 
induce both the transcription and secretion of TGF-ǃ (Reinhold et al; 1999) and the induction 
of TGF-ǃ can increase the apoptosis of NK cells (Poggi and Zocchi, 2006). TGF-ǃ and Tat 
have been detected in the sera of early HIV-1 infected individuals at levels that were 
biologically active in vitro (Reinhold et al; 1999). 
Some HIV-infected individuals have been shown to lose the ability of their cytotoxic T 
lymphocytes CTL (CD8+) to control infection in cells that carry HIV as well as other 
infectious agents (Pantaleo et al; 1993). About 25% of HIV infected individuals have been 
shown to produce TGF-ǃ1 in response to stimulation with HIV proteins or peptides (Garba 
et al; 2002). It has been shown that the loss of CTL activity is related to the production of 
TGF-ǃ1 in sufficient amounts to significantly reduce the IFN-Ǆ response of CD8+ cells to 
both HIV and other viral proteins such as vaccinia virus (Garba et al; 2002).  
It has been established that feline CD4+CD25+ T regulatory (T reg) cells share phenotypic 
and functional characteristics with human and murine T reg cells (Vahlenkamp et al; 2004). 
Early in the infection with feline immunodeficiency virus (FIV), CD4+CD25+ T reg cells 
exhibit increased expression of a membrane TGF- ǃ (mTGF-ǃ) (Mexas et al; 2008). The 
appearance of TGF-ǃ+CD4+CD25+ lymphocytes within the lymph node of FIV+ cats occurs in 
both acute and chronic FIV, even though mTGF-ǃ does not appear in the blood (Fogle et al; 
2010). There is also evidence of increased expression of TGF-ǃRII, the receptor of TGF-ǃ1, on 
CD8+ lymphocytes in FIV+ cats that would make the CD8+ lymphocytes much more 
sensitive to TGF-ǃ inhibition (Fogle et al; 2010). In FIV lentiviral infection, during both the 
acute and chronic stages of infection, CD4+CD25+ Tregs suppress CD8+ responses and the 
CD4+CD25+ Tregs use mTGF-ǃ to suppress IFN-Ǆ expression resulting in  suppression of  
CD8+ lymphocyte function (Fogle et al; 2010). These findings help explain the paradox of 
chronic HIV-1 infection, in which CD8+ T cells display an activated phenotype but exhibit 
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reduced effector function (Fogle et al; 2010, Bucci et al; 1998,  Tompkins and Tompkins 
2008). IL-10 and TGF- overlap with each other in many of their biological effects including 
inhibition of T cell proliferation and IFN- production (Othieno et al; 1999). 
12. Interleukin-10 (IL-10) 
IL-10 is an anti-inflammatory cytokine that essentially plays two regulatory roles in innate 
and adaptive immunity. It suppresses the up-regulation of various genes in macrophages 
and dendritic cells that are normally stimulated via toll-like receptors and promotes the 
proliferation of cytotoxic T cells, activates B cells, and induces the upregulation of specific 
genes in toll-like receptor activated phagocytic and dendritic cells (Trincheri, 2007). In 
addition, a critical function of IL-10 is its ability to inhibit pro-inflammatory cytokines such 
as TNF-ǂ, IFN-Ǆ, IL-1, IL-6, IL-2, and IL-12 (Trincheri, 2007). IL-10 decreases the production 
of pro-inflammatory cytokines by limiting the major histocompatibility class II and 
CD80/CD 86 expressed on monocytes and macrophage (Wang et al; 2005). IL-10 was 
believed to be produced by CD4+ Th2 cells; however, studies have shown that it is secreted 
by both Th1 and Th2 cells (Brockman et al; 2009). Also, cells from the myeloid lineage which 
include macrophages and dendritic cells also produce cytokine IL-10 (Hedrich and Bream, 
2010). Furthermore, IL-10 is regulated both at the transcriptional and post-translational level 
and is involved in various signaling pathways (Couper et al; 2008). 
There are several speculations of the role of IL-10 in HIV pathogenesis and the subject has 
been a popular interest in many studies. Ji et al., 2005 reported that CD14+ monocytes are 
the main cells producing cytokine IL-10 in PBMCs after HIV-1 infection via interactions 
independent of CD4+ molecules, thus, concluding that IL-10 production is dependent on the 
presence of CD14+ monocytes. Moreover, as the patient progresses to advanced stages of 
HIV disease, the frequency of IL-10 producing cells increases significantly (118). On the 
other hand, Naicker et al., 2009, stated that different stages of the HIV disease will govern 
what role IL-10 will play in infected individuals. For instance, in acute HIV-1 individuals, 
IL-10 may promote viral replication by inhibiting effector immune response from both arms 
of the innate and adaptive immunity (Naicker et al; 2009). Furthermore, it was proposed in a 
chronic phase, that IL-10 resembled a protective role by reducing immune activation, 
inhibiting virus replication in macrophages, and the increase in production of IL-10 levels 
lowered plasma viral load and increased CD4+ cell count (Naicker et al; 2009). 
13. HIV and free radicals 
It has been shown that HIV infection induces increased production of free radicals by 
macrophages. Free radical formation occurs as a byproduct of oxidative stress. Oxidative 
stress occurs when there is a disproportion between the reactive oxygen elements in the 
body versus the ability of the body to properly eliminate these reactive species. The 
presence of free radicals has been implicated in disturbing and damaging a number of 
biological processes (Karthikeyan et al; 2010). With regards to HIV infection the increase of 
oxidative stress has been seen to influence components in antioxidant defense in 
physiological antioxidants such as glutathione which are seen to decrease dramatically in 
HIV patients (Pace and Leaf, 1995). In addition to glutathione, vitamin A, C, and E at high 
doses as well as improving low levels of selenium were associated with assisting the 
prevention of HIV infection progression by working as antioxidants to remove free radicals 
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(Garland and Fawzi, 1999).  The aforementioned studies may provide a low cost method for 
improving the prognosis of HIV infected patients in high risk, underprivileged areas of the 
world. 
Chronic oxidative stress is often associated with HIV infection and research indicates a 
benefit for increased antioxidant vitamins and supplements in reduction of DNA base 
damage, which in turn can slow progression of infection (Jaruga et al; 2002). Neutrophils 
from asymptomatic HIV patients show increased oxygen radical production which can be 
modified by treating with N-acetyl cysteine, a compound used as an antioxidant (Smietana 
et al; 2008). The role of free radical oxidative stress on DNA damage is correlated with 
stimulated DNA repair mechanisms which activate enzymes associated with initiation of 
apoptosis such as poly ADP-ribose transferase and p53. Reduced NAD/NADH production 
would lower ATP synthesis that in turn correlates with a deficiency in glutathione; which as 
mentioned is an endogenous antioxidant important in resolving imbalance of free radicals 
(Dobmeyer et al; 1997).  
The progression of HIV is correlated with a decreased immunity. One way in which this 
decreased immunity progresses is by free radical overload of monocytes and granulocytes 
which leads to deficiency of antioxidant mechanisms which may lead to the loss of CD4 cells 
often seen in the progression of HIV (Dobmeyer et al; 1997). The decreased immunity may 
also be related to the reactive oxygen species and free radical presence which is higher in 
HIV infected patients. With HIV infection progression there is an increased production of 
reactive oxygen species which leads to the theory of free radical mediated apoptosis of 
lymphocytes which reduces the ability for immune response to progressive HIV infections 
(Dobmeyer et al; 1997). With regards to CD4 cell counts the apoptosis of lymphocytes by 
free radicals leads to progression of immunodeficiency and makes for a quicker transition 
from HIV infection to AIDS (Bautisita, 2001). It has been published that during HIV-1 
infection, hematopoietic cells are exposed to high amounts of free radicals. Subsequently 
there is a reduction of leukocytopoiesis and increase susceptibility to further infections 
(Masutani, 2000). Furthermore, there is a link to lipid peroxidation observed in patients with 
HIV or AIDS to a deficiency of antioxidants which leads to free radical proliferation (Favier 
et al; 1994 ).  
Rate of viral replication is a key process to the proliferation of HIV infection. The conditions 
in which viruses such as HIV will proliferate seem to correlate with the presence of 
oxidative stress/free radicals in vitro (Fuchs et al; 1991). There tends to be an increase in 
nuclear transcription factor and inflammatory cytokine activation of the immune system 
(Brach et al; 1992). The progression of the virus/infection will then allow for opportunistic 
infections which then would also promote more oxidative stress due to increased free 
radical elements, again improving viral replication and weakening antioxidant defense 
(Knysz, 2007).  
Damage or altering of the DNA repair machinery is an important aspect of the progression 
of HIV infection pathogenesis (Olinski et al; 2002).  There is a slow and deliberate 
degradation of cellular components such as membrane blebbing, chromatin condensation, 
and DNA cleavage ability.  Additionally, there is evidence that shows oxidative DNA 
damage will lead to the apoptotic cell death in HIV infected patients. There appears to be an 
increase in oxidatively modified DNA bases in HIV infected patients leading to what is 
known as pyrimidine and purine derived lesions. One specific lesion labeled, 8-OH-Gua 
was found in isolated lymphocytes of HIV patients. The presence of this lesion leads to 
transversions of DNA base pairs unless repaired before replication.  The number of these 
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lesions was seen to be reduced in response to antioxidant supplement and vitamin 
treatments, which correlates to free radical influence in DNA damage, and potential 
progression of HIV infection (Olinski et al; 2002).   
14. Conclusion 
Both HIV-1 and HIV-2 cause AIDS, but HIV-1 is found worldwide, whereas HIV-2 is found 
primarily in West Africa. Chemokine receptors, such as CXCR4 and CCR5 proteins, are 
required for the entry of HIV into CD4-positive cells. After establishing infection, HIV alters 
the synthesis of host cytokines and chemokines and kills CD4+ T lymphocytes thereby 
resulting in the loss of cell-mediated immunity and a high probability that the host will 
develop opportunistic infections.  
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